Why iPSC Is Research Thriving

In this first segment of Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas highlight the transformative potential of regenerative medicine and iPSC-based therapies. They emphasize the versatility and scalability of pluripotent stem cells, particularly for allogeneic applications that could eliminate the need for immunosuppression. These advances hold promise for treating complex diseases like diabetes, multiple sclerosis, and cardiac conditions, with the goal of making therapies more accessible and impactful on a global scale.